{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:33:14Z","timestamp":1767965594492,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Instituto Nacional de Sa\u00fade Dr. Ricardo Jorge"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Lipid measurements and genetic testing are the main diagnostic tools for FH screening that are available in many countries. A lipid profile is widely accessible, and genetic testing, although available worldwide, in some countries is only performed in a research context. Still FH is diagnosed late, showing lack of early screening programs worldwide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Pediatric screening of FH was recently recognized by the European Commission Public Health Best Practice Portal as one on the best practices in non-communicable disease prevention. The early diagnosis of FH and the lowering of LDL-C values over lifespan can reduce the risk of coronary artery disease and offer health and socioeconomic gains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Current knowledge about FH shows that early detection through appropriate screening needs to become a priority in healthcare systems worldwide. Governmental programs for FH identification should be implemented to unify the diagnosis and increase patient identification.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-023-01091-5","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T07:02:50Z","timestamp":1677740570000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?"],"prefix":"10.1007","volume":"25","author":[{"given":"A. M.","family":"Medeiros","sequence":"first","affiliation":[]},{"given":"M.","family":"Bourbon","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"20","key":"1091_CR1","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(20):2553\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1091_CR2","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"1091_CR3","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n J, John Chapman M, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Translational medicine. Eur Heart J. 2020;41.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"1091_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, Hovingh GK, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234\u201355.","journal-title":"Atherosclerosis"},{"issue":"10312","key":"1091_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","volume":"398","author":"AJ Vallejo-Vaz","year":"2021","unstructured":"Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, Dharmayat KI, Freiberger T, Hovingh GK, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713\u201325. This work summarizes the results from the European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC), a global registry of 42167 adults with clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia from 56 countries. The data reveals that earlier detection and greater use of combination therapies are required to reduce the global burden of FH.","journal-title":"Lancet"},{"issue":"16","key":"1091_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547\u201356. This work demonstrated that the initiation of statin therapy during childhood in patients with familial hypercholesterolemia slowed the progression of carotid intima-media thickness and reduced the risk of cardiovascular disease in adulthood.","journal-title":"N Engl J Med"},{"key":"1091_CR7","doi-asserted-by":"crossref","unstructured":"Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11).","DOI":"10.1002\/14651858.CD006401.pub5"},{"key":"1091_CR8","first-page":"337","volume":"11","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;11:337.","journal-title":"BMJ"},{"issue":"36","key":"1091_CR9","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425\u201337.","journal-title":"Eur Heart J"},{"issue":"6","key":"1091_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","volume":"72","author":"AC Sturm","year":"2018","unstructured":"Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia. J Am Coll Cardiol. 2018;72(6):662\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"1091_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","volume":"292","author":"U Ramaswami","year":"2020","unstructured":"Ramaswami U, Futema M, Bogsrud MP, Holven KB, Roeters van Lennep J, Wiegman A, et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2020;292:178\u201387. This work compares the characteristics and lipid levels of 3064 children with heterozygous familial hypercholesterolaemia from 8 European countries. The data suggest that many of the FH children are not receiving the full potential benefit of early identification and appropriate lipid-lowering treatment according to recommendations.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1091_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacl.2022.07.014","volume":"16","author":"SJ Spencer","year":"2022","unstructured":"Spencer SJ, Jones LK, Guzauskas GF, Hao J, Williams MS, Peterson JF, et al. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. J Clin Lipidol. 2022;16(5):667\u201375.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"1091_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jacl.2022.04.005","volume":"16","author":"R Gra\u00e7a","year":"2022","unstructured":"Gra\u00e7a R, Alves AC, Zimon M, Pepperkok R, Bourbon M. Functional profiling of LDLR variants: Important evidence for variant classification: functional profiling of LDLR variants. J Clin Lipidol. 2022;16(4):516\u201324. This work shows the important role that functional characterization plays in variant classification for an accurate diagnosis of FH.","journal-title":"J Clin Lipidol"},{"issue":"667","key":"1091_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3399\/bjgp18X694481","volume":"68","author":"N Qureshi","year":"2018","unstructured":"Qureshi N, Humphries SE, Gray H. Personalised medicine in general practice: the example of raised cholesterol. Br J Gen Pract. 2018;68(667):68.","journal-title":"Br J Gen Pract"},{"key":"1091_CR15","doi-asserted-by":"crossref","unstructured":"Gidding SS, Europe TF, Wiegman A, Groselj U, Freiberger T, Peretti N, et al. Paediatric familial hypercholesterolaemia screening in Europe \u2013 public policy background and recommendations. Eur J Prev Cardiol. 2022 Sep 5. This work summarizes the pediatric family screening programs in several European countries and outlines recommendations to improve identification of FH.","DOI":"10.1093\/eurjpc\/zwac200"},{"key":"1091_CR16","unstructured":"Paediatric screening of FH (familial hypercholesterolaemia) patients. European Commission Public Health Best Practice Portal. 2021. [Internet]. Available from: https:\/\/webgate.ec.europa.eu\/dyna\/bp-portal\/practice.cfm?id=390. Accessed 12 Sept 2022"},{"issue":"34","key":"1091_CR17","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/eurheartj\/ehac224","volume":"43","author":"U Groselj","year":"2022","unstructured":"Groselj U, Wiegman A, Gidding SS. Screening in children for familial hypercholesterolaemia: start now. Eur Heart J. 2022;43(34):3209\u201312. A viewpoint on the different pediatric family screening programs in Europe and the public policy recommendations addressed at the Technical Meeting of 2021 Slovenian EU presidency.","journal-title":"Eur Heart J"},{"issue":"5","key":"1091_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1194\/jlr.P043182","volume":"55","author":"AM Medeiros","year":"2014","unstructured":"Medeiros AM, Alves AC, Aguiar P, Bourbon M. Pediatric investigators of the Portuguese familial hypercholesterolemia study Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia. J Lipid Res. 2014;55(5):947\u201355.","journal-title":"J Lipid Res"},{"issue":"3","key":"1091_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/cge.13697","volume":"97","author":"C Mariano","year":"2020","unstructured":"Mariano C, Alves AC, Medeiros AM, Chora JR, Antunes M, Futema M, et al. The familial hypercholesterolaemia phenotype: monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. Clin Genet. 2020;97(3):457\u201366.","journal-title":"Clin Genet"},{"key":"1091_CR20","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/genes12081168","volume":"12","author":"LC Zuurbier","year":"2021","unstructured":"Zuurbier LC, Defesche JC, Wiegman A. Successful genetic screening and creating awareness of familial hypercholesterolemia and other heritable dyslipidemias in the Netherlands. Genes (Basel). 2021;12:1168.","journal-title":"Genes (Basel)"},{"key":"1091_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2018.06.858","volume":"277","author":"U Groselj","year":"2018","unstructured":"Groselj U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. Atherosclerosis. 2018;277:383\u201391.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1091_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12887-019-1586-4","volume":"19","author":"A Kreissl","year":"2019","unstructured":"Kreissl A, Walleczek N, Espina PR, Hallwirth U, Greber-Platzer S. Selective screening for familial hypercholesterolemia in Austrian children - first year results. BMC Pediatr. 2019;19(1):1\u20137.","journal-title":"BMC Pediatr"},{"issue":"3","key":"1091_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/eurpub\/ckac007","volume":"32","author":"V Sanin","year":"2022","unstructured":"Sanin V, Schmieder R, Ates S, Schlieben LD, Wiehler J, Sun R, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022;32(3):422\u20138.","journal-title":"Eur J Public Health"},{"issue":"18","key":"1091_CR24","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1177\/2047487316666371","volume":"23","author":"L Mundal","year":"2016","unstructured":"Mundal L, Veier\u00f8d MB, Halvorsen T, Holven KB, Ose L, Iversen PO, et al. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994\u20132009, a registry study. Eur J Prev Cardiol. 2016;23(18):1962\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"1091_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33549\/physiolres.933600","volume":"66","author":"M Vrabl\u00edk","year":"2017","unstructured":"Vrabl\u00edk M, Vaclov\u00e1 M, Tich\u00fd L, So\u0161ka V, Bl\u00e1ha V, Fajkusov\u00e1 L, et al. Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed PROJECT. Physiol Res. 2017;66:1\u20139.","journal-title":"Physiol Res"},{"issue":"11","key":"1091_CR26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","volume":"67","author":"L Perez De Isla","year":"2016","unstructured":"Perez De Isla L, Alonso R, Watts GF, Mata N, SaltijeralCerezo A, Mu\u00f1iz O, et al. Attainment of LDl-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67(11):1278\u201385.","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"1091_CR27","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","volume":"38","author":"M Kerr","year":"2017","unstructured":"Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832\u20139.","journal-title":"Eur Heart J"},{"issue":"3 SUPPL","key":"1091_CR28","first-page":"495","volume":"89","author":"RM Lauer","year":"1992","unstructured":"Lauer RM, Barness LA, Clark R, Deckelbaum RJ, Finberg L, Kwiterovich PO, et al. National Cholesterol Education Program (NCEP): Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89(3 SUPPL):495\u2013501.","journal-title":"Pediatrics"},{"issue":"SUPP. 5","key":"1091_CR29","first-page":"S213","volume":"128","author":"JM De Jesus","year":"2011","unstructured":"De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(SUPP. 5):S213.","journal-title":"Pediatrics"},{"issue":"185","key":"1091_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jpeds.2016.12.078","volume":"1","author":"SD de Ferranti","year":"2017","unstructured":"de Ferranti SD, Rodday AM, Parsons SK, Cull WL, O\u2019Connor KG, Daniels SR, et al. Cholesterol screening and treatment practices and preferences: a survey of United States pediatricians. J Pediatr. 2017;1(185):99-105.e2.","journal-title":"J Pediatr"},{"key":"1091_CR31","unstructured":"Portuguese Directorate General of Health (DGS). Norma da Dire\u00e7\u00e3o-geral da sa\u00fade n. 10\/2013. Programa Nacional de Sa\u00fade Infantil e Juvenil. 2013."},{"issue":"11","key":"1091_CR32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/clc.22050","volume":"35","author":"PO Kwiterovich","year":"2012","unstructured":"Kwiterovich PO, Gidding SS. Universal screening of cholesterol in children. Clin Cardiol. 2012;35(11):662\u20134.","journal-title":"Clin Cardiol"},{"key":"1091_CR33","doi-asserted-by":"crossref","unstructured":"Sustar U, Kordonouri O, Mlinaric M, Kovac J, Arens S, Sedej K, et al. Universal screening for familial hypercholesterolemia in 2 populations. Genet Med. 2022 Aug 1.","DOI":"10.2139\/ssrn.4035402"},{"issue":"17","key":"1091_CR34","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","volume":"375","author":"DS Wald","year":"2016","unstructured":"Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child\u2013parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2016;375(17):1628\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"1091_CR35","first-page":"281","volume":"58","author":"AC Martin","year":"2022","unstructured":"Martin AC, Hooper AJ, Norman R, Nguyen LT, Burnett JR, Bell DA, et al. Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. 2022;58(2):281\u20137.","journal-title":"Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia"},{"issue":"275","key":"1091_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","volume":"1","author":"AJ McKay","year":"2018","unstructured":"McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1\u20132 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis. 2018;1(275):434\u201343.","journal-title":"Atherosclerosis"},{"key":"1091_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","volume":"29","author":"A Pirillo","year":"2017","unstructured":"Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, et al. Spectrum of mutations in Italian patients with familial hypercholesterolemia: new results from the LIPIGEN study. Atheroscler Suppl. 2017;29:17\u201324.","journal-title":"Atheroscler Suppl"},{"key":"1091_CR38","unstructured":"Bedlington N, Abifadel M, Beger B, Bourbon M, Bueno H, Ceska R, et al. The time is now: achieving FH paediatric screening across Europe - the Prague Declaration. GMS Heal Innov Technol. 2022;16:Doc04. This political document is a result of the Czech EU Presidency meeting on FH paediatric screening and addresses the barriers to the implementation of FH paediatric screening across Europe and also concrete actions needed to move forward."},{"key":"1091_CR39","unstructured":"Familial hypercholesterolaemia: identification and management [Internet]. Familial hypercholesterolaemia: identification and management: evidence reviews for case-finding, diagnosis and statin monotherapy. National Institute for Health and Care Excellence (NICE); 2017."},{"issue":"1","key":"1091_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskina KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"8","key":"1091_CR41","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamacardio.2021.1301","volume":"6","author":"AC Sturm","year":"2021","unstructured":"Sturm AC, Truty R, Callis TE, Aguilar S, Esplin ED, Garcia S, et al. Limited-variant screening vs comprehensive genetic testing for familial hypercholesterolemia diagnosis. JAMA Cardiol. 2021;6(8):902\u20139.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"1091_CR42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14737159.2017.1332997","volume":"17","author":"MA Iacocca","year":"2017","unstructured":"Iacocca MA, Hegele RA. Recent advances in genetic testing for familial hypercholesterolemia. Expert Rev Mol Diagn. 2017;17(7):641\u201351.","journal-title":"Expert Rev Mol Diagn"},{"issue":"9","key":"1091_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14737159.2021.1953985","volume":"21","author":"S Ibrahim","year":"2021","unstructured":"Ibrahim S, Defesche JC, Kastelein JJP. Beyond the usual suspects: expanding on mutations and detection for familial hypercholesterolemia expert review of molecular diagnostics. Expert Rev Mol Diagn. 2021;21(9):887\u201395.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"1091_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-018-0731-0","volume":"20","author":"AJ Hooper","year":"2018","unstructured":"Hooper AJ, Burnett JR, Bell DA, Watts GF. The present and the future of genetic testing in familial hypercholesterolemia: opportunities and caveats. Curr Atheroscler Reports. 2018;20(6):1\u20137.","journal-title":"Curr Atheroscler Reports"},{"issue":"8","key":"1091_CR45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/eurjpc\/zwaa451","volume":"28","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Tromp TR, Defesche JC, Grefhorst A, Stroes ESG, Hovingh GK, et al. Next-generation sequencing to confirm clinical familial hypercholesterolemia. Eur J Prev Cardiol. 2021;28(8):875\u201383.","journal-title":"Eur J Prev Cardiol"},{"issue":"262","key":"1091_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2017.04.002","volume":"1","author":"M Bourbon","year":"2017","unstructured":"Bourbon M, Alves AC, Alonso R, Mata N, Aguiar P, Padr\u00f3 T, et al. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: the SAFEHEART registry. Atherosclerosis. 2017;1(262):8\u201313.","journal-title":"Atherosclerosis"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01091-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:39:31Z","timestamp":1679884771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01091-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01091-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"2 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}